Pharmaceuticals News and Research

RSS

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

IBM study reveals the need for smart drug manufacturer supply chain systems

Reducing the risk of counterfeit drugs and contaminated medications amidst the complexity of global manufacturing are among the top concerns of the pharmaceutical and life sciences industries today, according to a new IBM (NYSE: IBM) study. More than 50 percent of executives polled say their companies fail to respond quickly enough to pandemics and other emergencies because of lapses in their supply chain.

10 Sep 2009

Complete Genomics sequences and delivers 14 human genomes

Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009.

10 Sep 2009

Luna Innovations posts year-on-year decline in second-quarter 2009 revenues

Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended June 30, 2009.

10 Sep 2009

TI Pharma: A role model of public-private cooperation and partnership

The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute.

10 Sep 2009

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Ore Pharmaceuticals Inc., announced today the publication of an article in the online version of the journal Inflammation Research titled, “Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.”

10 Sep 2009

Healthcare reform explained

A bevy of legislation is flooding Capitol Hill on healthcare reform. With President Obama’s speech kicking debate on these initiatives into high gear, Eric Zimmerman, a partner in the Health Law Department of leading law firm McDermott Will & Emery, weighs in on the issues:

10 Sep 2009

Physicians and patients underestimate promotional volume of Actonel

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patients and physicians most frequently recall Roche's Boniva messages among the ten surveyed osteoporosis brands likely as a result of the Sally Field marketing campaign.

10 Sep 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

arGEN-X BV announces first closing of its Series A equity financing round

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months.

10 Sep 2009

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Covance expands global footprint with new clinical development offices

Covance Inc. (NYSE: CVD) today announced the opening of new clinical development offices in Sao Paolo, Brazil and Mexico City, Mexico. These offices further expand Covance's global footprint with a comprehensive range of services across Latin America. Earlier this year, Covance announced new offices in Santiago, Chile and Lima, Peru.

10 Sep 2009

Baucus aims for health agreement in advance of Obama speech tonight

Democrats are promising to send President Obama a health reform plan this year as Senate Finance Committee Chairman Max Baucus continues to try to get key Republicans on board with a new proposal.

9 Sep 2009

American Medical News examines clinical trials outsourcing

American Medical News examines the ethical considerations of outsourcing pharmaceutical clinical trials to developing countries. The article highlights how it is less expensive for a drug company to conduct a trial in India, where it runs about $2,000 to track a patient through a trial, compared to the cost in the U.S., which is "10 times more."

9 Sep 2009

American Asthma Foundation awards $750,000 for asthma research

Dr. Serpil Erzurum, one of the nation's leading experts in asthma, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Erzurum will collaborate with experts in nuclear medicine and physics to develop an innovative way for clinicians to observe changes in the lungs of patients during an asthma attack.

9 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

CEO Cancer Gold Standard accreditation for ASCO

The American Society of Clinical Oncology (ASCO) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

9 Sep 2009